J&J – Talk Bio

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

3 weeks ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push

4 weeks ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy, CD388, Cidara Therapeutics, Influenza, J&J, Merck, Phase 3, sanofi, United States Food and Drug Administration

Merck; Cidara Therapeutics; CD388; antiviral; acquisition; influenza; phase 3; FDA Breakthrough Therapy; J&J; Sanofi; Keytruda

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

2 months ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials

No Trump Drug Pricing Plan for J&J—Yet

2 months ago talkbio0Tagged drug pricing plan, J&J, Transplant Registry Unified Management Program

J&J; Trump; Drug Pricing Plan

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

2 months ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

6 months ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear

6 months ago talkbio0Tagged Akeega, Amplitude, Approved, BRCA, HRR gene, Inhibitor, J&J, Malignant neoplasm of prostate, mCSPC, Metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, Mutation, PARP1 gene, United States Food and Drug Administration

Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)